Press release
Gastric Cancer Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated)
Key Takeaways from the Gastric Cancer Pipeline Report
* DelveInsight's Gastric Cancer pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Gastric Cancer treatment.
* The leading Gastric Cancer Companies working in the market include Linton Pharm Co. Ltd., Shanghai Henlius Biotech, RAPT Therapeutics, AstraZeneca, Astellas Pharma, Minneamrita Therapeutics, Aston Science, Servier Bio-Innovation LLC, Bukwang Pharmaceutical, Taiho Oncology, Inc., Novartis Pharmaceuticals, Base Therapeutics (Shanghai) Co., Ltd, Shanghai Miracogen Inc., RemeGen Co., Ltd., Idience Co., Ltd., BeiGene, Ono Pharmaceutical Co. Ltd, Elevar Therapeutics, R-Pharm, Innovent Biologics (Suzhou) Co. Ltd., MacroGenics, Sichuan Baili Pharmaceutical Co., Ltd., LianBio LLC, and Janssen Pharmaceutical, and others.
* Promising Gastric Cancer Therapies in the various stages of development include Avelumab, BBI608, Camrelizumab, Catumaxomab, RAPA-201, SHR-1210, Amivantamab, Atezolizumab, Bevacizumab, Cabozantinib, Cinrebafusp alfa, Crizotinib, DKN-01, DP303c, Eflornithine, EP0057, Epacadostat, FLX475, Futibatinib, GEN-001, HLX07, HLX22, Infigratinib, KH903, Lenvatinib, Masitinib, MAX-40279, MRG002, MRG003, Niraparib, Savolitinib, Minnelide, SHR-1701, Margetuximab, Bemarituzumab, Evorpacept, Lenvatinib, CDK-004, TPX-0022, TCRx_T Cells, IN10018, IMU-131, SOT102, CT041, AB011, Zanidatamab, NC410, PT 886, PRS-343, Oraxol, CA-4948, Q702, ACE1702, SI-B001, TT-4, LUM015, LB 1908, CUE-102, TORL-2-307-MAB, OBI-833/OBI-821, ASP2138, NC410, SO-C101, HC-5404-FU, CPL304110, LNS8801, RGX-202-01, A166, GZ17-6.02, HMPL-453, CCT303-406, VMD-928, ITI 4000, PAb 001, and others.
* April 2024: Singlera Genomics Inc-The objective is to explore the clinical performance of polygene methylation (PCR-fluorescence probe) in the adjunctive diagnosis of gastric cancer, including the sensitivity of detection of various types and stages of gastric cancer, the specificity of detection of healthy controls, precancerous states, precancerous lesions, and the detection interference of other cancers. The diagnostic performance will be compared with CA199, CEA and CA724. The research data will provide a basis for screening targets for the development of detection kits.
* March 2024:- Vivian Wing Yan Lee- This is a retrospective cost-minimization analysis study to compare the costs of treatment with EOF vs EOX regimens in patients with gastric cancer (GC) in Hong Kong. Patient baseline characteristics and cost data will be extracted from records and compared. The oral chemotherapy agent Xeloda Registered was recently extended by the Hong Kong Hospital Authority as subsidized therapy for the treatment of colorectal cancer1.
* February 2024:- Bristol-Myers Squibb- The purpose of this study is to determine the efficacy and safety of investigational drug relatlimab plus nivolumab in combination with chemotherapy in participants with unresectable, untreated, locally advanced or metastatic gastric or GEJ cancer. A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (Anti-LAG-3) and Nivolumab in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy as First-Line Treatment in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma.
* February 2024:- Ambrx Inc.- A Phase 1, Multicenter, Open-label, Multiple Dose-escalation and Expansion Study of ARX788, as Monotherapy in Advanced Solid Tumors With HER2 Expression. This 2-part, Phase 1, open-label study will determine the recommended Phase 2 dose (RP2D) of ARX788 in subjects with advanced HER2 positive cancers and will assess the safety and anticancer activity in breast, gastric and other advanced HER2 positive solid tumors.
Request a sample and discover the recent advances in Gastric Cancer @ Gastric Cancer Pipeline Outlook Report [https://www.delveinsight.com/sample-request/gastric-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Gastric Cancer Overview
Stomach cancer is cancer that starts anywhere inside the stomach or the stomach wall. It's also called gastric cancer. Stomach cancer is more common in older people. Around 50 out of 100 cases (around 50%) occur in people aged 75 or over. It is more common in men than women. About 95% of the time, stomach cancer starts in the stomach lining and progresses slowly. Many stomach cancers are linked to lifestyle or environmental factors, including diet. Stomach cancer is linked with a bacteria that lives in the stomach called Helicobacter pylori. But not everyone with Helicobacter pylori will develop stomach cancer.
Gastric Cancer Emerging Drugs Profile
* Catumaxomab: Linton Pharm Co. Ltd.
* HLX10: Shanghai Henlius Biotech
* FLX475: RAPT Therapeutics
* Savolitinib: AstraZeneca/HUTCHMED
* ASP 2138: Astellas Pharma
* Minnelide : Minneamrita Therapeutics LLC
Learn more about the Gastric Cancer in clinical trials @ Gastric Cancer Drugs [https://www.delveinsight.com/sample-request/gastric-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Gastric Cancer Therapeutics Assessment
There are approx. 180+ Gastric Cancer companies which are developing the Gastric Cancer therapies. The Gastric Cancer companies which have their Gastric Cancer drug candidates in the most advanced stage, i.e. phase III include, Linton Pharm Co. Ltd.
DelveInsight's Gastric Cancer pipeline report covers around 200+ products under different phases of clinical development like
* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
Discover more about Gastric Cancer in development @ Gastric Cancer Clinical Trials [https://www.delveinsight.com/sample-request/gastric-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Gastric Cancer Companies
Linton Pharm Co. Ltd., Shanghai Henlius Biotech, RAPT Therapeutics, AstraZeneca, Astellas Pharma, Minneamrita Therapeutics, Aston Science, Servier Bio-Innovation LLC, Bukwang Pharmaceutical, Taiho Oncology, Inc., Novartis Pharmaceuticals, Base Therapeutics (Shanghai) Co., Ltd, Shanghai Miracogen Inc., RemeGen Co., Ltd., Idience Co., Ltd., BeiGene, Ono Pharmaceutical Co. Ltd, Elevar Therapeutics, R-Pharm, Innovent Biologics (Suzhou) Co. Ltd., MacroGenics, Sichuan Baili Pharmaceutical Co., Ltd., LianBio LLC, and Janssen Pharmaceutical, and others.
Gastric Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical.
* Molecule Type
Gastric Cancer Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
To learn more about Gastric Cancer, visit @ Gastric Cancer Segmentation [https://www.delveinsight.com/sample-request/gastric-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Gastric Cancer Pipeline Report
* Coverage- Global
* Gastric Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Gastric Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Gastric Cancer Companies- Linton Pharm Co. Ltd., Shanghai Henlius Biotech, RAPT Therapeutics, AstraZeneca, Astellas Pharma, Minneamrita Therapeutics, Aston Science, Servier Bio-Innovation LLC, Bukwang Pharmaceutical, Taiho Oncology, Inc., Novartis Pharmaceuticals, Base Therapeutics (Shanghai) Co., Ltd, Shanghai Miracogen Inc., RemeGen Co., Ltd., Idience Co., Ltd., BeiGene, Ono Pharmaceutical Co. Ltd, Elevar Therapeutics, R-Pharm, Innovent Biologics (Suzhou) Co. Ltd., MacroGenics, Sichuan Baili Pharmaceutical Co., Ltd., LianBio LLC, and Janssen Pharmaceutical, and others.
* Gastric Cancer Therapies- Avelumab, BBI608, Camrelizumab, Catumaxomab, RAPA-201, SHR-1210, Amivantamab, Atezolizumab, Bevacizumab, Cabozantinib, Cinrebafusp alfa, Crizotinib, DKN-01, DP303c, Eflornithine, EP0057, Epacadostat, FLX475, Futibatinib, GEN-001, HLX07, HLX22, Infigratinib, KH903, Lenvatinib, Masitinib, MAX-40279, MRG002, MRG003, Niraparib, Savolitinib, Minnelide, SHR-1701, Margetuximab, Bemarituzumab, Evorpacept, Lenvatinib, CDK-004, TPX-0022, TCRx_T Cells, IN10018, IMU-131, SOT102, CT041, AB011, Zanidatamab, NC410, PT 886, PRS-343, Oraxol, CA-4948, Q702, ACE1702, SI-B001, TT-4, LUM015, LB 1908, CUE-102, TORL-2-307-MAB, OBI-833/OBI-821, ASP2138, NC410, SO-C101, HC-5404-FU, CPL304110, LNS8801, RGX-202-01, A166, GZ17-6.02, HMPL-453, CCT303-406, VMD-928, ITI 4000, PAb 001, and others.
For further information on the Gastric Cancer pipeline therapeutics, reach out @ Gastric Cancer Products Development [https://www.delveinsight.com/sample-request/gastric-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Gastric Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Late Stage Products (Phase III)
* Comparative Analysis
* Catumaxomab : Neovii Biotech
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* FLX475: RAPT Therapeutics
* Early Stage Products (Phase I)
* Comparative Analysis
* ASP 2138: Astellas Pharma
* Inactive Products
* Gastric Cancer Key Companies
* Gastric Cancer Key Products
* Gastric Cancer - Unmet Needs
* Gastric Cancer - Market Drivers and Barriers
* Gastric Cancer - Future Perspectives and Conclusion
* Gastric Cancer Analyst Views
* Gastric Cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=gastric-cancer-pipeline-outlook-fda-approvals-clinical-trials-and-companies-2024-updated]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Gastric Cancer Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated) here
News-ID: 3486224 • Views: …
More Releases from ABNewswire
Deos Hair Care Launches its New Hair Growing Shampoo and Conditioner
Image: https://www.abnewswire.com/uploads/782c46f2e762751974c37b0afe469f34.png
Deos Hair Care [https://www.deoshaircare.com/] has launched its new Hair Growth Shampoo and Conditioner, formulated to help people struggling with thinning hair and hair loss. Completely free from paraben, sulfate, and aluminum, this luxury, high-performing, healthy product packs the power of strengthening, reinvigorating, and DHT-blocking ingredients, including caffeine, biotin, rosemary oil, keratin, castor seed oil, and panthenol.
Deos Hair Care has named their product lines Adonis and Aphrodite, after the Greek…
Cake Run Celebrates Recognition as Melbourne's Top Cake Delivery Service
A Melbourne cake delivery service known for its wide range of dietary-specific options and dedication to inclusivity has won the community's hearts.
Cake Run [https://cakerun.com.au/], a prominent cake delivery service in Melbourne, has quickly gained recognition as the city's foremost provider of high-quality cakes catering to diverse dietary needs. Founded in 2022, the company has set a new standard in the cake delivery industry, offering a broad array of cakes that…
NMT Auto Service Hosts Free BBQ Event in Oakville
Oakville Auto Repair shop invites community for a day of food, fun, and prizes.
NMT Auto Service [http://www.nmtoakville.com/] is excited to announce a Free BBQ event on June 15, from 10 AM to 4 PM, in Oakville, Ontario. This community appreciation event will feature a variety of attractions, including complimentary burgers and drinks, a live band, and a chance to win a free set of Michelin tires. The free BBQ is…
Schneider Electric Unveils Resi9 Energy Center Retrofit Innovation for Prosumer …
- New intelligent electrical panel secures electrical installations in homes equipped with new energy landscape devices and renewables
- 2024 marks 100 years of circuit breakers in homes, the devices in our electrical panels that protect our homes' electricity
- Prioritizing safety is crucial when adding solar panels, battery back-up, and electric vehicle chargers to homes
Schneider Electric, the leader in the digital transformation of energy management and automation, today launched its Resi9…
More Releases for Gastric
Gastric Balloon Market: Global Industry Analysis Report 2018
The Gastric Balloon market was valued at Million US$ in 2017 and is projected to reach Million US$ by 2025, at a CAGR of during the forecast period. In this study, 2017 has been considered as the base year and 2018 to 2025 as the forecast period to estimate the market size for Gastric Balloon.
This study focuses on the production side and consumption side of Gastric Balloon, presents the global…
The Virtual Gastric Band 101
There’s been a lot in the media recently about the Hypnotic Gastric Band or also known as The Virtual Gastric Band. I get asked a lot about it so thought I’d give a Virtual Gastric Band 101 on what it is, but more importantly what it’s not.
The Virtual Gastric Band - It is a non-surgical technique which uses the power of hypnosis to retrain the person to be satisfied with smaller…
Coastal Cosmetics Reshape Gastric Balloon Webinar
Those who are in the dieting industry and related fields, as well as professional medical clinicians, know that weight loss is a hard and complex struggle. In many cases, weight loss is the best way to deal with chronic conditions and prevent major health threats, even those that can be potentially fatal. At the same time, lifestyle changes may not accomplish the results that a patient needs.
The Reshape gastric balloon…
Global Gastric Ulcers Therapeutic Pipeline Review, H2 2017
"The Report Gastric Ulcers - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastric Ulcers - Pipeline Review, H2 2017, provides an overview of the Gastric Ulcers (Gastrointestinal) pipeline landscape.
Gastric ulcer is a painful sore or ulcer in the lining of stomach. The most common cause of…
BRIC Bariatric Surgery Devices Market Segments - Bariatric Stapling Devices, Gas …
"The Report BRIC Bariatric Surgery Devices Market Outlook to 2023 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
GlobalDatas new report, "BRIC Bariatric Surgery Devices Market Outlook to 2023", provides key market data on the BRIC Bariatric Surgery Devices market. The report provides value, in millions of US dollars, volume (in units) and and average prices (USD) within market segments -…
Global Gastric Banding Market Research Report 2017
This report studies Gastric Banding in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering
Roche
Abbott
Siemens
Alere
Nova
Request Sample Report:
http://www.reportbazzar.com/request-sample/?pid=887564&ptitle=Global+Gastric+Banding+Market+Research+Report+2017&req=Sample
Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of Gastric Banding in these regions, from 2011 to 2021…
